{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:08Z","timestamp":1790285948509,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Science and Technology Innovation Startup Fund of Fujian Maternal and Child Health Hospital","award":["YCXY 23-02"],"award-info":[{"award-number":["YCXY 23-02"]}]},{"name":"the Science and Technology Innovation Startup Fund of Fujian Maternal and Child Health Hospital","award":["YCXY 23-02"],"award-info":[{"award-number":["YCXY 23-02"]}]},{"name":"the Science and Technology Innovation Startup Fund of Fujian Maternal and Child Health Hospital","award":["YCXY 23-02"],"award-info":[{"award-number":["YCXY 23-02"]}]},{"name":"the Science and Technology Innovation Startup Fund of Fujian Maternal and Child Health Hospital","award":["YCXY 23-02"],"award-info":[{"award-number":["YCXY 23-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00228-023-03520-5","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T14:02:49Z","timestamp":1686664969000},"page":"1013-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"79","author":[{"given":"Fuxin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiana","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"2","key":"3520_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263\u2013272. https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest"},{"issue":"2","key":"3520_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccl.2015.12.002","volume":"34","author":"F Pistoia","year":"2016","unstructured":"Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A (2016) The epidemiology of atrial fibrillation and stroke. Cardiol Clin 34(2):255\u2013268. https:\/\/doi.org\/10.1016\/j.ccl.2015.12.002","journal-title":"Cardiol Clin"},{"issue":"12","key":"3520_CR3","first-page":"1359","volume":"74","author":"AF Members","year":"2016","unstructured":"Members AF, Kirchhof P, Benussi S et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J 74(12):1359","journal-title":"Eur Heart J"},{"key":"3520_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","volume":"50","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 50:e1\u2013e88","journal-title":"Eur J Cardiothorac Surg"},{"key":"3520_CR5","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jacc.2016.01.072","volume":"67","author":"C Becattini","year":"2016","unstructured":"Becattini C, Agnelli G (2016) Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol 67:1941\u20131955","journal-title":"J Am Coll Cardiol"},{"key":"3520_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197583","volume":"13","author":"RCP Makam","year":"2018","unstructured":"Makam RCP, Hoaglin DC, McManus DD, Wang V, Gore JM, Spencer FA et al (2018) Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis. PLoS ONE 13:e0197583","journal-title":"PLoS ONE"},{"key":"3520_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00e5s U, Bergqvist D et al (2010) Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202\u2013204","journal-title":"J Thromb Haemost"},{"key":"3520_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2021.03.004","volume":"2021","author":"L Tittl","year":"2021","unstructured":"Tittl L, Marten S, Naue C, Beyer-Westendorf J (2021) 5-year outcomes from rivaroxaban therapy in atrial fibrillation: results from the Dresden NOAC Registry. Thromb Res 2021:24\u201330. https:\/\/doi.org\/10.1016\/j.thromres.2021.03.004","journal-title":"Thromb Res"},{"issue":"2","key":"3520_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.21315\/mjms2022.29.2.15","volume":"29","author":"AS Abdullah","year":"2022","unstructured":"Abdullah AS, Tan HP, Mohd SS (2022) Bleeding and thromboembolic events in patients with non-valvular atrial fibrillation treated with apixaban or rivaroxaban. Malays J Med Sci 29(2):164\u2013172. https:\/\/doi.org\/10.21315\/mjms2022.29.2.15. Epub 21 Apr 2022","journal-title":"Malays J Med Sci"},{"key":"3520_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"issue":"1","key":"3520_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Angers U, Bergqvist D et al (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202\u2013204","journal-title":"J Thromb Haemost"},{"key":"3520_CR12","unstructured":"Higgins JPT (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0. Chichester, England: The Cochrane Collaboration"},{"issue":"17","key":"3520_CR13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","volume":"376","author":"H Calkins","year":"2017","unstructured":"Calkins H, Willems S, Gerstenfeld EP et al (2017) Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 376(17):1627\u20131636","journal-title":"N Engl J Med"},{"key":"3520_CR14","first-page":"107424842092948","volume":"17","author":"TW Chapin","year":"2020","unstructured":"Chapin TW, Leedahl D, Brown AB et al (2020) Comparison of anticoagulants for postoperative atrial fibrillation after coronary artery bypass grafting: a pilot study. J Cardiovasc Pharmacol Ther 17:107424842092948","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"03","key":"3520_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1160\/TH10-07-0451","volume":"105","author":"N Chung","year":"2011","unstructured":"Chung N, Jeon H, Lien L et al (2011) Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 105(03):535\u2013545","journal-title":"Thromb Haemost"},{"issue":"12","key":"3520_CR16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fbrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"32","key":"3520_CR17","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","volume":"39","author":"MD Ezekowitz","year":"2018","unstructured":"Ezekowitz MD, Pollack CV, Halperin JL et al (2018) Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 39(32):2959\u20132971","journal-title":"Eur Heart J"},{"issue":"22","key":"3520_CR18","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruf CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fbrillation. N Engl J Med 369(22):2093\u20132104","journal-title":"N Engl J Med"},{"issue":"10055","key":"3520_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","volume":"388","author":"A Goette","year":"2016","unstructured":"Goette A, Merino JL, Ezekowitz MD et al (2016) Edoxaban versus enoxaparin\u2013warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388(10055):1995\u20132003","journal-title":"Lancet"},{"issue":"11","key":"3520_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fbrillation. N Engl J Med 365(11):981\u2013992","journal-title":"N Engl J Med"},{"key":"3520_CR21","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1093\/eurheartj\/ehz190","volume":"36","author":"SH Hohnloser","year":"2019","unstructured":"Hohnloser SH, John C, Riccardo C et al (2019) Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J 36:3013\u20133021","journal-title":"Eur Heart J"},{"issue":"9","key":"3520_CR22","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N et al (2012) Rivaroxaban v warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study. Circ J 76(9):2104\u20132111","journal-title":"Circ J"},{"issue":"12","key":"3520_CR23","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jacep.2018.08.003","volume":"4","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kashimura S, Nishiyama T et al (2018) Asymptomatic Cerebral Infarction During Catheter Ablation for Atrial Fibrillation: Comparing Uninterrupted Rivaroxaban and Warfarin (ASCERTAIN). JACC Clin Electrophysiol 4(12):1598\u20131609","journal-title":"JACC Clin Electrophysiol"},{"issue":"32","key":"3520_CR24","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","volume":"39","author":"P Kirchhof","year":"2018","unstructured":"Kirchhof P, Haeusler KG, Blank B et al (2018) Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 39(32):2942\u20132955","journal-title":"Eur Heart J"},{"issue":"5","key":"3520_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jce.12928","volume":"27","author":"T Kuwahara","year":"2016","unstructured":"Kuwahara T, Abe M, Yamaki M et al (2016) Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol 27(5):549\u2013554","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"16","key":"3520_CR26","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. New Engl J Med 380(16):1509\u20131524","journal-title":"New Engl J Med"},{"issue":"4","key":"3520_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/1708538113490423","volume":"22","author":"L Mao","year":"2013","unstructured":"Mao L, Li C, Li T et al (2013) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular 22(4):252\u2013258","journal-title":"Vascular"},{"issue":"8","key":"3520_CR28","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","volume":"75","author":"S Ogawa","year":"2011","unstructured":"Ogawa S, Shinohara Y, Kanmuri K (2011) Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation -the ARISTOTLE-J study. Circ J 75(8):1852\u20131859","journal-title":"Circ J"},{"issue":"10","key":"3520_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahafey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"issue":"3","key":"3520_CR30","first-page":"633","volume":"103","author":"JI Weitz","year":"2010","unstructured":"Weitz JI, Connolly SJ, Patel I et al (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 103(3):633\u2013641","journal-title":"Thromb Haemost"},{"issue":"8","key":"3520_CR31","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","volume":"76","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Koretsune Y, Yasaka M et al (2012) Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 76(8):1840\u20131847","journal-title":"Circ J"},{"issue":"2","key":"3520_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10840-015-0053-x","volume":"44","author":"D Lu","year":"2015","unstructured":"Lu D, Zhang Q, Liu Q, Wang K, Wang S, Shan Q (2015) Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis. J Interv Card Electrophysiol 44(2):105\u2013111. https:\/\/doi.org\/10.1007\/s10840-015-0053-x","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"3520_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10557-012-6426-9","volume":"27","author":"JS Kwong","year":"2013","unstructured":"Kwong JS, Lam YY, Yan BP, Yu CM (2013) Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther 27(1):23\u201335. https:\/\/doi.org\/10.1007\/s10557-012-6426-9","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"3520_CR34","doi-asserted-by":"publisher","first-page":"e0144856","DOI":"10.1371\/journal.pone.0144856","volume":"10","author":"AT Cohen","year":"2015","unstructured":"Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, Tushabe D, Batson S (2015) Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 10(12):e0144856. https:\/\/doi.org\/10.1371\/journal.pone.0144856","journal-title":"PLoS One"},{"issue":"4","key":"3520_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.amjcard.2014.11.039","volume":"115","author":"L Touma","year":"2015","unstructured":"Touma L, Filion KB, Atallah R, Eberg M, Eisenberg MJ (2015) A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists. Am J Cardiol 115(4):533\u2013541. https:\/\/doi.org\/10.1016\/j.amjcard.2014.11.039. Epub 2 Dec 2014","journal-title":"Am J Cardiol"},{"issue":"12","key":"3520_CR36","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.07.026","volume":"24","author":"J Chen","year":"2015","unstructured":"Chen J, Zhuang X, Long M, Su C, Wang L (2015) Efficacy and safety of edoxaban in nonvalvular atrial fibrillation: a meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis 24(12):2710\u20132719. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2015.07.026. Epub 29 Aug 2015","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"10","key":"3520_CR37","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.cjca.2013.07.005","volume":"29","author":"M Shurrab","year":"2013","unstructured":"Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D, Lashevsky I, Healey JS, Crystal E (2013) Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol 29(10):1203\u20131210. https:\/\/doi.org\/10.1016\/j.cjca.2013.07.005. Epub 29 Aug 2013","journal-title":"Can J Cardiol"},{"key":"3520_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijcard.2015.03.323","volume":"187","author":"R Nairooz","year":"2015","unstructured":"Nairooz R, Sardar P, Pino M, Aronow WS, Sewani A, Mukherjee D, Paydak H, Maskoun W (2015) Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. Int J Cardiol 187:345\u2013353. https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.323. Epub 21 Mar 2015","journal-title":"Int J Cardiol"},{"issue":"3","key":"3520_CR39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10840-020-00784-0","volume":"58","author":"Y Sun","year":"2020","unstructured":"Sun Y, Liu X, Xu Y (2020) Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation. J Interv Card Electrophysiol 58(3):381\u2013399. https:\/\/doi.org\/10.1007\/s10840-020-00784-0. Epub 27 May 2020","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"3520_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12872-022-02550-8","volume":"22","author":"ZY Liu","year":"2022","unstructured":"Liu ZY, Zhang HX, Ma LY, Mu GY, Xie QF, Zhou S, Wang ZN, Wang Z, Hu K, Xiang Q, Cui YM (2022) Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies. BMC Cardiovasc Disord 22(1):105. https:\/\/doi.org\/10.1186\/s12872-022-02550-8","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"3520_CR41","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.cjca.2015.09.012","volume":"32","author":"R Nairooz","year":"2016","unstructured":"Nairooz R, Ayoub K, Sardar P, Payne J, Almomani A, Pothineni NV, Shailesh F, Aronow WS, Mukherjee D (2016) Uninterrupted new oral anticoagulants compared with uninterrupted vitamin K antagonists in ablation of atrial fibrillation: a meta-analysis. Can J Cardiol 32(6):814\u2013823. https:\/\/doi.org\/10.1016\/j.cjca.2015.09.012","journal-title":"Can J Cardiol"},{"key":"3520_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jpm9010007","volume":"9","author":"SH Kanuri","year":"2019","unstructured":"Kanuri SH, Kreutz RP (2019) Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med 9:7","journal-title":"J Pers Med"},{"key":"3520_CR43","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/europace\/euv124","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel H, Vrijens B (2015) Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twicedaily regimens and their potential impact on medication adherence. Europace 17:1317\u20131318","journal-title":"Europace"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03520-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:06:13Z","timestamp":1689926773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3520"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03520-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}